View More Recent Stories

Sep 26, 2024 06:28AM H.C. Wainwright Reiterates Buy Rating on Celldex Therapeutics (CLDX)
Sep 25, 2024 04:01PM Guggenheim on Celldex Therapeutics (CLDX): 'We continue to think today's stock reaction is overdone'
Sep 25, 2024 02:33PM Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
Sep 25, 2024 11:02AM Celldex (CLDX) Halted on Volatility, Down 21% Following 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Sep 25, 2024 10:45AM Celldex (CLDX) Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
Aug 8, 2024 06:12PM Celldex (CLDX) Tops Q2 EPS by 5c
Jul 29, 2024 04:59PM Celldex (CLDX) Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
Jul 16, 2024 08:02AM Celldex (CLDX) Initiates Global Phase 3 Program for Barzolvolimab
Jun 17, 2024 04:07PM Stifel Starts Celldex Therapeutics (CLDX) at Buy
Jun 11, 2024 05:00AM Wolfe Research Starts Celldex Therapeutics (CLDX) at Outperform
View More Recent Stories